CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX) Short Interest Down 39.0% in August

CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX) was the recipient of a significant decline in short interest in August. As of August 31st, there was short interest totaling 788,894 shares, a decline of 39.0% from the August 15th total of 1,293,928 shares. Based on an average trading volume of 4,573,541 shares, the short-interest ratio is currently 0.2 days.

CNBX Pharmaceuticals Price Performance

Shares of CNBX opened at $0.00 on Wednesday. CNBX Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $0.00.

CNBX Pharmaceuticals Company Profile

CNBX Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the research and development of synthetic cannabinoid-based drug candidates. The company’s proprietary platform applies medicinal chemistry techniques to design novel small-molecule analogs of naturally occurring cannabinoids, aiming to improve efficacy and safety compared with existing therapies. Its pipeline includes multiple preclinical compounds targeting neuropathic and chronic pain, with a goal of advancing these candidates through IND-enabling studies.

Headquartered in Costa Mesa, California, CNBX Pharmaceuticals collaborates with contract research organizations and academic partners to conduct pharmacology and toxicology studies as well as scale up manufacturing processes.